Trial record 3 of 15 for: glutamate antagonist | Parkinson Disease

Previous Study | Return to List | Next Study

Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00001365

Recruitment Status : Completed

First Posted : December 10, 2002

Last Update Posted : July 13, 2006

Sponsor:

Information provided by:

National Institutes of Health Clinical Center (CC)

Study Description

Brief Summary:

This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease.

Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease.

Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.

Condition or disease	Intervention/treatment	Phase
Neurodegenerative Disease Parkinson's Disease	Drug: dextromethorphan	Phase 2

Detailed Description:

The ability of the putative excitatory amino acid receptor antagonist, dextromethorphan, to modify psychomotor function safely in patients with neurodegenerative disease will be evaluated using a modified double-blind placebo-controlled design. Therapeutic activity will be rated at various doses by means of standard motor and cognitive performance scales. Safety will be assessed at frequent intervals by clinical observation and laboratory tests.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Enrollment :	42 participants
Primary Purpose:	Treatment
Official Title:	NMDA Receptor Antagonist Treatment of Neurodegenerative Disease
Study Start Date :	July 1993
Study Completion Date :	June 2001

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Parkinson disease

MedlinePlus related topics: Degenerative Nerve Diseases Parkinson's Disease

Drug Information available for: Dextromethorphan hydrobromide Dextromethorphan

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Parkinson's disease or other neurodegenerative disorders in which excessive stimulation of central glutamatergic pathways is hypothesized.

Patients must be in good general health and have no history or clinical evidence of significant cardiac (including dysrhythmias), pulmonary, gastrointestinal, renal, hepatic, endocrine, hematological or psychiatric disease.

Patient must not evidence any disorder which in the opinion of the investigator imposes an unnecessary risk to the patient or compromises the scientific interpretation of the data.

Individuals of child bearing potential must practice appropriate methods of birth control.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001365

Locations

Layout table for location information

United States, Maryland
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)

More Information

Publications:

Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev. 1997 Jul;21(4):447-53. Review.

Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord. 1998 May;13(3):414-7.

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00001365 History of Changes
Other Study ID Numbers:	930183 93-N-0183
First Posted:	December 10, 2002 Key Record Dates
Last Update Posted:	July 13, 2006
Last Verified:	July 2000

Keywords provided by National Institutes of Health Clinical Center (CC):


Dextromethorphan Dextrorphan Glutamate Antagonist Parkinson's Disease

Additional relevant MeSH terms:

Layout table for MeSH terms

Parkinson Disease Neurodegenerative Diseases Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders	Excitatory Amino Acid Antagonists Dextromethorphan Antitussive Agents Respiratory System Agents Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs

To Top